Progress towards a hepatitis C virus vaccine

Emerging Microbes and Infections

Volumn 2, Issue , 2013, Pages

  Man John Law, Lok ^a   Landi, Abdolamir ^a   Magee, Wendy C ^a   Lorne Tyrrell, D ^a   Houghton, Michael ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

HCV; hepatitis; infection; prophylactic; therapeutic; vaccine

Indexed keywords

HEPATITIS C VACCINE; NEUTRALIZING ANTIBODY;

CELLULAR IMMUNITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMORAL IMMUNITY; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; T LYMPHOCYTE; VIROLOGY; VIRUS LIKE AGENT;

EID: 84921484801     PISSN: None     EISSN: 22221751     Source Type: Journal    
DOI: 10.1038/emi.2013.77     Document Type: Review

References (76)

1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359-362.
2. Ciesek S, Manns MP. Hepatitis in 2010: the dawn of a new era in HCV therapy. Nat Rev Gastroenterol Hepatol 2011; 8: 69-71.
3. Chatel-Chaix L, Germain MA, Gotte M, Lamarre D. Direct-acting and host-targeting HCV inhibitors: current and future directions. Curr Opin Virol 2012; 2: 588-598.
4. Tanaka Y, Nishida N, Sugiyama M et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-1109.
5. Ge D, Fellay J, Thompson AJ et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
6. Susser S, Vermehren J, Forestier N et al. Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir. J Clin Virol 2011; 52: 321-327.
7. Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2010; 138: 447-462.
8. Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol. 2007; 5: 453-463.
9. Simmonds P, Bukh J, Combet C et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005; 42: 962-973.
10. Gottwein JM, Bukh J. Cutting the gordian knot-development and biological relevance of hepatitis C virus cell culture systems. Adv Virus Res 2008; 71: 51-133.
11. Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 2006; 55: 1350-1359.
12. Afdhal NH. The natural history of hepatitis C. Semin Liver Dis 2004; 24 (Suppl 2): 3-8.
13. Walker CM. Adaptive immunity to the hepatitis C virus. Adv Virus Res 2010; 78: 43-86.
14. Grakoui A, Shoukry NH, Woollard DJ et al. HCV persistence and immune evasion in the absence of memory T cell help. Science 2003; 302: 659-662.
15. Shoukry NH, Grakoui A, Houghton M et al. Memory CD81 T cells are required for protection from persistent hepatitis C virus infection. J Exp Med 2003; 197: 1645-1655.
16. Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 2001; 194: 1395-1406.
17. Thimme R, Bukh J, Spangenberg HC et al. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci USA 2002; 99: 15661-15668.
18. Lauer GM, Barnes E, Lucas M et al. High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. Gastroenterology 2004; 127: 924-936.
19. Logvinoff C, Major ME, Oldach D et al. Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc Natl Acad Sci USA 2004; 101: 10149-10154.
20. Farci P, Shimoda A, Coiana A et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 2000; 288: 339-344.
21. Farci P, Shimoda A, Wong D et al. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci USA 1996; 93: 15394-15399.
22. von Hahn T, Yoon JC, Alter H et al. Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology 2007; 132: 667-678.
23. Dowd KA, Netski DM, Wang XH, Cox AL, Ray SC. Selection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus. Gastroenterology 2009; 136: 2377-2386.
24. HijikataM, Shimizu YK, Kato H et al. Equilibrium centrifugation studies of hepatitis C virus: evidence for circulating immune complexes. J Virol 1993; 67: 1953-1958.
25. Bartosch B, Dubuisson J, Cosset FL. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med 2003; 197: 633-642.
26. Hsu M, Zhang J, Flint M et al. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci USA 2003; 100: 7271-7276.
27. Wakita T, Pietschmann T, Kato T et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005; 11: 791-796.
28. Lindenbach BD, Evans MJ, Syder AJ et al. Complete replication of hepatitis C virus in cell culture. Science 2005; 309: 623-626.
29. Osburn WO, Fisher BE, DowdKA et al. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology 2010; 138: 315-324.
30. Pestka JM, Zeisel MB, Blaser E et al. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci USA 2007; 104: 6025-6030.
31. DahariH, Feinstone SM, Major ME. Meta-analysis of hepatitis C virus vaccine efficacy in chimpanzees indicates an importance for structural proteins. Gastroenterology 2010; 139: 965-974.
32. Burton DR, Poignard P, Stanfield RL, Wilson IA. Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science 2012; 337: 183-186.
33. Haynes BF, Gilbert PB, McElrath MJ et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012; 366: 1275-1286.
34. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361: 2209-2220.
35. Raghuraman S, Park H, Osburn WO, Winkelstein E, Edlin BR, Rehermann B. Spontaneous clearance of chronic hepatitis C virus infection is associated with appearance of neutralizing antibodies and reversal of T-cell exhaustion. J Infect Dis 2012; 205: 763-771.
36. Baumert TF, Wellnitz S, Aono S et al. Antibodies against hepatitis C virus-like particles and viral clearance in acute and chronic hepatitis C. Hepatology 2000; 32: 610-617.
37. Houghton M. Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses. Immunol Rev 2011; 239: 99-108.
38. Frey SE, Houghton M, Coates S et al. Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Vaccine 2010; 28: 6367-6373.
39. Farci P, Alter HJ, Govindarajan S et al. Lack of protective immunity against reinfection with hepatitis C virus. Science 1992; 258: 135-140.
40. Prince AM, Brotman B, Lee DH et al. Protection against chronic hepatitis C virus infection after rechallenge with homologous, but not heterologous, genotypes in a chimpanzee model. J Infect Dis 2005; 192: 1701-1709.
41. Shimizu YK, Igarashi H, Kiyohara T et al. A hyperimmune serum against a synthetic peptide corresponding to the hypervariable region 1 of hepatitis C virus can prevent viral infection in cell cultures. Virology 1996; 223: 409-412.
42. Meunier JC, Russell RS, Goossens V et al. Isolation and characterization of broadly neutralizing human monoclonal antibodies to the e1 glycoprotein of hepatitis C virus. J Virol 2008; 82: 966-973.
43. Verstrepen BE, Depla E, Rollier CS et al. Clearance of genotype 1b hepatitis C virus in chimpanzees in the presence of vaccine-induced E1-neutralizing antibodies. J Infect Dis 2011; 204: 837-844.
44. Lapierre P, Troesch M, Alvarez F, Soudeyns H. Structural basis for broad neutralization of hepatitis C virus quasispecies. PLoS ONE 6: 2011; e26981.
45. Meunier JC, Gottwein JM, HoughtonMet al. Vaccine-induced cross-genotype reactive neutralizing antibodies against hepatitis C virus. J Infect Dis 2011; 204: 1186-1190.
46. Stamataki Z, Coates S, Abrignani S, Houghton M, McKeating JA. Immunization of human volunteers with hepatitis C virus envelope glycoproteins elicits antibodies that cross-neutralize heterologous virus strains. J Infect Dis 2011; 204: 811-813.
47. Law JL, Chen C, Wong J et al. A hepatitis C virus (HCV) vaccine comprising envelope glycoproteins gpE1/gpE2 derived from a single isolate elicits broad cross-genotype neutralizing antibodies in humans. PLoS ONE 2013; 8: e59776.
48. Brimacombe CL, Grove J, Meredith LW et al. Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission. J Virol 2011; 85: 596-605.
49. Tarr AW, Lafaye P, Meredith L et al. An alpaca nanobody inhibits hepatitis C virus entry and cell-to-cell transmission. Hepatology 2013; 58: 932-939.
50. Fofana I, Xiao F, Thumann C et al. A novel monoclonal anti-CD81 antibody produced by genetic immunization efficiently inhibits hepatitis C virus cell-cell transmission. PLoS ONE 2013; 8: e64221.
51. Public Health Agency of Canada. Canadian Immunization Guide. Ottawa: PHAS, 2006. Available at http://www.phac-aspc.gc.ca (accessed 1 July 2013).
52. Akazawa D, Moriyama M, Yokokawa H et al. Neutralizing antibodies induced by cell culture-derived hepatitis C virus protect against infection in mice. Gastroenterology 2013; 145: 447-455.e1-4.
53. Narbus CM, Israelow B, Sourisseau M et al. HepG2 cells expressing microRNA miR-122 support the entire hepatitis C virus life cycle. J Virol 2011; 85: 12087-12092.
54. da Costa D, Turek M, Felmlee DJ et al. Reconstitution of the entire hepatitis C virus life cycle in nonhepatic cells. J Virol 2012; 86: 11919-11925.
55. Steenbergen RH, Joyce MA, Thomas BS et al. Human serum leads to differentiation of human hepatoma cells, restoration of VLDL secretion and a 1000-fold increase in HCV JFH-1 titers. Hepatology 2013; doi:10.1002/hep.26566.
56. Garrone P, Fluckiger AC, Mangeot PE et al. A prime-boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaques. Sci Transl Med 2011; 3: 94-71.
57. Gerlach JT, Diepolder HM, Jung MC et al. Recurrence of hepatitis C virus after loss of virus-specific CD41 T-cell response in acute hepatitis C. Gastroenterology 1999; 117: 933-941.
58. Cooper S, Erickson AL, Adams EJ et al. Analysis of a successful immune response against hepatitis C virus. Immunity 1999; 10: 439-449.
59. Christie JM, Healey CJ, Watson J et al. Clinical outcome of hypogammaglobulinaemic patients following outbreak of acute hepatitis C: 2 year follow up. Clin Exp Immunol 1997; 110: 4-8.
60. Post JJ, Pan Y, Freeman AJ et al. Clearance of hepatitis C viremia associated with cellular immunity in the absence of seroconversion in the hepatitis C incidence and transmission in prisons study cohort. J Infect Dis 2004; 189: 1846-1855.
61. Barnes E, Folgori A, Capone S et al. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med 2012; 4: 115-1.
62. Folgori A, Capone S, Ruggeri L et al. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat Med 2006; 12: 190-197.
63. ClinicalTrials.gov. Staged Phase I/II Hepatitis C Prophylactic Vaccine, Identifier NCT01436357. Bethesda: NIH, 2012. Available at http://clinicaltrials.gov/ct2/show/NCT01436357 (accessed 1 July 2013).
64. Polakos NK, Drane D, Cox J et al. Characterization of hepatitis C virus core-specific immune responses primed in rhesus macaques by a nonclassical ISCOM vaccine. J Immunol 2001; 166: 3589-3598.
65. Drane D, Maraskovsky E, Gibson R et al. Priming of CD41 and CD81 T cell responses using a HCV core ISCOMATRIX vaccine: a phase I study in healthy volunteers. Hum Vaccin 2009; 5: 151-157.
66. Habersetzer F, Honnet G, Bain C et al. A poxvirus vaccine is safe, induces T-cell responses, and decreases viral load in patients with chronic hepatitis C. Gastroenterology 2011; 141: 890-899.
67. Wedemeyer H, Janczewska-Kazek E, WlodzimierzMet al. Significant improvement of complete EVR in HCVac phase II clinical trial when adding TG4040 therapeutic vaccine to PegIFNa2a and ribavirin. J Hepatol 2012; 56(Suppl 2): S552.
68. ClinicalTrials.gov. Study of a Novel Therapeutic Vaccine Against Hepatitis C Using Ad6NSmut and MVA-NSmut in Chronically Infected Patients, Identifier NCT01701336. Bethesda: NIH, 2012. Available at http://clinicaltrials.gov (accessed 1 July 2013).
69. ClinicalTrials.gov. CHRONVAC-C Study Followed by Standard of Care in Chronic Hepatitis C Virus (HCV) Subjects, Identifier NCT01335711. Bethesda: NIH, 2011. Available at http://clinicaltrials.gov (accessed 1 July 2013).
70. Canadian Cancer Society. Liver cancer on the rise. Toronto: CCS, 2013. Available at http://www.cancer.ca (accessed 1 July 2013).
71. SweetingMJ, de Angelis D, Brant LJ, Harris HE, Mann AG, Ramsay ME. The burden of hepatitis C in England. J Viral Hepat 2007; 14: 570-576.
72. Smith BD, Morgan RL, Beckett GA et al. Recommendations for the Identification of Chronic Hepatitis C Virus Infection Among Persons Born During 1945-1965. MMWR Recomm Rep 2012; 61 (RR-4): 1-32.
73. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol 2013; 10: 553-562.
74. Thomas DL, Thio CL, Martin MP et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801.
75. Suppiah V, Moldovan M, Ahlenstiel G et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-1104.
76. Khakoo SI, Thio CL, Martin MP et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 2004; 305: 872-874.